TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03585062
Drug: S1,
Normalized name: Vaccine product containing only S, preS1, preS2 Hepatitis B virus recombinant surface antigens
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
Study: NCT02974114
Drug: Paracetamol and caffeine
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product containing 500 mg paracetamol and 65 mg caffeine
Study: NCT03138070
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719 400 mg daily by mouth continue for 14 days
Study: NCT03855228
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of placebo administered as a nasal spray for 15 days.
Study: NCT03855228
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of placebo administered as an oral tablet for 15 days.
Study: NCT04462770
Drug: EPX-100 (clemizole HCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of EPX-100
Study: NCT04462770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of placebo
Study: NCT01443208
Drug: desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
Study: NCT01443208
Drug: desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
Study: NCT01443208
Drug: desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
Study: NCT00816959
Drug: R-mabHDI and ABVD
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
Study: NCT00914888
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered.
Study: NCT00914888
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Study: NCT01358045
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Application on the lesion 2 times a day 8 weeks.
Study: NCT00244322
Drug: LY450139 dihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00244322
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01128842
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1500 mg/m\^2 twice daily by mouth.
Study: NCT00319501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular autoinjector; administered at onset of an episode
Study: NCT00427128
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
Study: NCT00427128
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 13-36.
Study: NCT00617461
Drug: GEn 1200mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg/day gabapentin enacarbil
Study: NCT00617461
Drug: GEn 3600mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3600mg/day gabapentin enacarbil
Study: NCT00650299
Drug: Xanax XR® Tablets 3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg, single dose fed
Study: NCT03784261
Drug: Drug: Salirumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: To examine the effects of salirumab in RA patients
Study: NCT03784261
Drug: Drug: Tocilizmab
Approvals — FDA: no, EMA: no, PMDA: no
Description: To examine the effects of tocilizmab in RA patients
Study: NCT03402893
Drug: ONEXTON Topical Gel
Normalized name: Onexton Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onexton gel applied once daily to face
Study: NCT00803842
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
Study: NCT05491720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo tablet (Galenus pharmaceutical company)
Study: NCT00795145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, Placebo control for blinding, Normal Saline, Single dose
Study: NCT00981201
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)
Study: NCT00981201
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)
Study: NCT00981201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Months 1-3:~By mouth twice daily.
Study: NCT00981201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Months 4-6:~By mouth twice daily.
Study: NCT01199965
Drug: MAP0004
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
Study: NCT01199965
Drug: IV DHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV DHE administered at Visit 2 or 3 as per protocol
Study: NCT00319956
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
Study: NCT02051686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive a similar volume load of normal saline and maintenance doses.
Study: NCT02405780
Drug: FKB327
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
Study: NCT02405780
Drug: Humira®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
Study: NCT02272868
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
Study: NCT02122081
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04550949
Drug: QL1206
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
Study: NCT02678195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
Study: NCT01251926
Drug: EZN-2208
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00265304
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01576588
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
Study: NCT02762097
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline would be injected into uterine cavity to delineate defects
Study: NCT02579096
Drug: Placebo, vehicle control (febuxostat-shaped)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets resembling febuxostat will be given with allopurinol.
Study: NCT02579096
Drug: Placebo, vehicle control (allopurinol-shaped)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules resembling allopurinol will be given with febuxostat.
Study: NCT00547547
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
Study: NCT02494713
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
Study: NCT03657342
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator.
Study: NCT03777033
Drug: Prophylactic protocol with Ca and Vit D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g calcium /day for 5 days and then 2g/day for 10 days 2 Micrograms Alfacalcidol/day and then 1 microgram /day for 10 days~the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet
Study: NCT00159965
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: flexible dose placebo
Study: NCT00311961
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00311961
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02202525
Drug: Micardis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02793544
Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.
Study: NCT03565029
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capecitabine and Oxaliplatin (4x cycles)
Study: NCT02793544
Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.
Study: NCT02793544
Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.
Study: NCT02793544
Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~* Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~* Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight.
Study: NCT00449878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02046928
Drug: A6
Normalized name: CYP2A6
Approvals — FDA: no, EMA: no, PMDA: no
Description: A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
Study: NCT02495324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of placebo PO daily
Study: NCT04282980
Drug: DCC-2618
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral kinase inhibitor
Study: NCT03763110
Drug: antibiotic paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: An antibiotic mixture composed of ciproﬂoxacin, metronidazole, and minocycline, known as triple antibiotic paste (TAP) or 3mix, has been the most widely used medicament, This goes back to the studies by Hoshino et al.1996
Study: NCT03558477
Drug: YYD601 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYD601 1
Study: NCT02004704
Drug: GZ402665
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion
Study: NCT01848730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02564796
Drug: Epoetin Alfa and Iron
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
Study: NCT02564796
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
Study: NCT03583697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
Study: NCT03996486
Drug: BAY1093884
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
Study: NCT00114530
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An initial intravenous dose of 500 mg/m\^2 was followed by 11 infusions of 750 mg/m\^2 with mesna given for bladder protection.
Study: NCT03572972
Drug: Antiplatelets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for NVAF patients
Study: NCT01817530
Drug: 0.5 mg estradiol / 0.1 mg norethindrone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral hard capsule
Study: NCT01817530
Drug: 1 mg estradiol / 0.5 mg norethindrone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral hard capsule
Study: NCT01817530
Drug: E2/NETA placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral hard capsule
Study: NCT00001880
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
Study: NCT01073995
Drug: Kenalog and Sensorcaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
Study: NCT01968798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg enteric-coated placebo, taken daily
Study: NCT02598102
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac for pain relief
Study: NCT02467400
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00287482
Drug: Essiac
Normalized name: ESSIAC TEA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02975336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to M2951 orally for 52 weeks.
Study: NCT03305055
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Information included in arm descriptions
Study: NCT00622908
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of ISV-403 TID, 5 days
Study: NCT00866684
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: control arm Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
Study: NCT03268382
Drug: APR-246
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00750997
Drug: hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
Study: NCT03274596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03268382
Drug: Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT03302650
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive normal saline.
Study: NCT03302650
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive norepinephrine infusion adjusted according to blood pressure
Study: NCT01694264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
Study: NCT03658135
Drug: BIIB092
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB092 is an investigational monoclonal antibody directed at tau protein
Study: NCT01545635
Drug: Fresh Frozen Plasma blood type 0, A, B and AB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT\>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
Study: NCT03198013
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04195906
Drug: Experimental: SNF472
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks